

Daftar Pustaka

1. Chandril C. Acute Ischemic Stroke: Management Approach. *Indian Journal of Critical Care Medicine*. 2019 Jun 1;23(S2):140–6.
2. Murphy SJX, Werring DJ. Stroke: causes and clinical features. *Medicine*. 2020 Sep;48(9):561–6.
3. Patil S, Rossi R, Jabrah D, Doyle K. Detection, Diagnosis and Treatment of Acute Ischemic Stroke: Current and Future Perspectives. *Front Med Technol*. 2022 Jun 24;4.
4. Alawneh KZ, Qawasmeh M Al, Raffee LA, Al-Mistarehi AH. Ischemic stroke demographics, clinical features and scales and their correlations: an exploratory study from Jordan. *Future Sci OA*. 2022 Aug;8(7).
5. Venketasubramanian N, Yudianto FL, Tugasworo D. Stroke Burden and Stroke Services in Indonesia. *Cerebrovasc Dis Extra*. 2022 Mar 21;12(1):53–7.
6. Salvadori E, Papi G, Insalata G, Rinnoci V, Donnini I, Martini M, et al. Comparison between Ischemic and Hemorrhagic Strokes in Functional Outcome at Discharge from an Intensive Rehabilitation Hospital. *Diagnostics*. 2020 Dec 28;11(1):38.
7. Pożarowszczyk N, Kurkowska-Jastrzębska I, Sarzyńska-Długosz I, Nowak M, Karliński M. Reliability of the modified Rankin Scale in clinical practice of stroke units and rehabilitation wards. *Front Neurol*. 2023 Mar 3;14.
8. Jin XX, Fang MD, Hu LL, Yuan Y, Xu JF, Lu GG, et al. Elevated lactate dehydrogenase predicts poor prognosis of acute ischemic stroke. *PLoS One*. 2022 Oct 7;17(10):e0275651.
9. M. Tóth O, Menyhárt Á, Frank R, Hantosi D, Farkas E, Bari F. Tissue Acidosis Associated with Ischemic Stroke to Guide Neuroprotective Drug Delivery. *Biology (Basel)*. 2020 Dec 11;9(12):460.
10. LIN AQ, SHOU JX, LI XY, MA L, ZHU XH. Metabolic changes in acute cerebral infarction: Findings from proton magnetic resonance spectroscopic imaging. *Exp Ther Med*. 2014 Feb;7(2):451–5.
11. Cecil KM. Proton Magnetic Resonance Spectroscopy. *Neuroimaging Clin N Am*. 2013 Aug;23(3):381–92.
12. Thau L, Reddy V, Singh P. Anatomy, Central Nervous System. *StatPearls [Internet] Treasure Island (FL)*. 2022;
13. Konan LM, Reddy V, Mesfin FB. Neuroanatomy, Cerebral Blood Supply. *StatPearls Treasure Island (FL): StatPearls Publishing*. 2023;
14. Rilianto B, Kurniawan R, Rajab N, Prasetyo B. Endovascular Thrombectomy for Acute Ischemic Stroke in Indonesia: Challenging and

- Strategic Planning. *Neuropsychiatr Dis Treat*. 2024 Mar;Volume 20:621–30.
15. Kuriakose D, Xiao Z. Pathophysiology and Treatment of Stroke: Present Status and Future Perspectives. *Int J Mol Sci*. 2020 Oct 15;21(20):7609.
 16. Su Z, Ye Y, Shen C, Qiu S, Sun Y, Hu S, et al. Pathophysiology of Ischemic Stroke: Noncoding RNA Role in Oxidative Stress. *Oxid Med Cell Longev*. 2022 Sep 12;2022:1–12.
 17. Salaudeen MA, Bello N, Danraka RN, Ammani ML. Understanding the Pathophysiology of Ischemic Stroke: The Basis of Current Therapies and Opportunity for New Ones. *Biomolecules*. 2024 Mar 4;14(3):305.
 18. Ojaghihaghghi S, Vahdati SS, Mikaeilpour A, Ramouz A. Comparison of neurological clinical manifestation in patients with hemorrhagic and ischemic stroke. *World J Emerg Med*. 2017;8(1):34.
 19. Hui C, Tadi P, Patti L. Ischemic Stroke. *StatPearls Treasure Island (FL)*. 2022;
 20. Allen et al. Sequence-specific MR Imaging Findings That Are Useful in Dating Ischemic Stroke. *Radiographics*, 2012.
 21. Christiansen S. Ischemic stroke thrombus characterization through quantitative magnetic resonance imaging. 2021.
 22. Busto G, Morotti A, Carlesi E, Fiorenza A, Di Pasquale F, Mancini S, et al. Pivotal role of multiphase computed tomography angiography for collateral assessment in patients with acute ischemic stroke. *Radiol Med*. 2023 Jun 23;128(8):944–59.
 23. Sotoudeh H, Bag AK, Brooks MD. “Code-Stroke” CT Perfusion; Challenges and Pitfalls. *Acad Radiol*. 2019 Nov;26(11):1565–79.
 24. Lucena AF de, Castro-Afonso LH de, Monsignore LM, Nakiri GS, Fábio SRC, Pontes Neto O, et al. Carotid artery stenting in the context of endovascular treatment of acute ischemic stroke. *Arq Neuropsiquiatr*. 2016 Mar;74(3):212–8.
 25. Bang OY. Multimodal MRI for Ischemic Stroke: From Acute Therapy to Preventive Strategies. *Journal of Clinical Neurology*. 2009;5(3):107.
 26. Lin Q et al, Metabolic changes in acute cerebral infarction: Findings from proton magnetic resonance spectroscopic imaging, *Experimental And Therapeutic Medicine* 7: 451-455, 2014
 27. Bertoldo D, Watcharakorn A, Castillo M. Brain proton magnetic resonance spectroscopy. Introduction and overview. *Neuroimag Clin N Am* 2013; 23:359-380.
 28. Ferris JK, Neva JL, Vavasour IM, Attard KJ, Greeley B, Hayward KS, et al. Cortical *N*-acetylaspartate concentrations are impacted in chronic stroke but do not relate to motor impairment: A magnetic resonance spectroscopy study. *Hum Brain Mapp*. 2021 Jul 3;42(10):3119–30.

29. Dani KA, An L, Henning EC, Shen J, Warach S. Multivoxel MR Spectroscopy in Acute Ischemic Stroke. *Stroke*. 2012 Nov;43(11):2962–7.
30. Bulakbasi N. Clinical applications of proton MR spectroscopy in the diagnosis of brain tumours. *Spectroscopy*. 2004;18(2):143–53.
31. Herpich F, Rincon F. Management of Acute Ischemic Stroke. *Crit Care Med*. 2020 Nov;48(11):1654–63.
32. Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, et al. 2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. *Stroke*. 2018 Mar;49(3).
33. Pożarowszczyk N, Kurkowska-Jastrzębska I, Sarzyńska-Długosz I, Nowak M, Karliński M. Reliability of the modified Rankin Scale in clinical practice of stroke units and rehabilitation wards. *Front Neurol*. 2023 Mar 3;14.
34. JL Saver et al. Standardized Nomenclature for Modified Rankin Scale Global Disability Outcomes: Consensus Recommendations From Stroke Therapy Academic Industry Roundtable XI. *Stroke*. 2021 Sep;52(9):3054–62.
35. M Fouad et al. Prediction of Functional Outcome in Ischemic Stroke Patients: An Observational Study on Egyptian Population. *Cureus*. 2017 Jun 26;
36. Zihni E, McGarry BL, Kelleher JD. Moving Toward Explainable Decisions of Artificial Intelligence Models for the Prediction of Functional Outcomes of Ischemic Stroke Patients. In: *Digital Health*. Exon Publications; 2022. p. 73–90.
37. Broderick JP, Adeoye O, Elm J. Evolution of the Modified Rankin Scale and Its Use in Future Stroke Trials. *Stroke*. 2017 Jul;48(7):2007–12.
38. LW Andersen et al. Etiology and Therapeutic Approach to Elevated Lactate Levels. *Mayo Clin Proc*. 2013 Oct;88(10):1127–40.
39. M Cai et al. Lactate Is Answerable for Brain Function and Treating Brain Diseases: Energy Substrates and Signal Molecule. *Front Nutr*. 2022 Apr 28;9.
40. Y Zhong et al. Association between lactate/albumin ratio and 28-day all-cause mortality in ischemic stroke patients without reperfusion therapy: a retrospective analysis of the MIMIC-IV database. *Front Neurol*. 2023 Oct 12;14.
41. S Jo et al. Initial hyperlactatemia in the ED is associated with poor outcome in patients with ischemic stroke. *Am J Emerg Med*. 2012 Mar;30(3):449–55.

42. Komsiska D. Oxidative stress and stroke: a review of upstream and downstream antioxidant therapeutic options. *Comp Clin Path.* 2019 Aug 9;28(4):915–26.
43. Pujiati et al, Peranan Short dan Long Time Echo Pada Pemeriksaan Magnetic Resonance Spectroscopy Dengan Klinis Tumor Otak. Politeknik Kesehatan Semarang, Agustus 2020.
44. Nesyia et al. Characteristics and Risk Factors of Patients with Acute Ischemic Stroke in Dr. Hasan Sadikin General Hospital Bandung, Indonesia. *Althea Medical Journal.* 2022;9(4):218–222.
45. Cvoro et al. Associations Between Diffusion and Perfusion Parameters, N-Acetyl Aspartate, and Lactate in Acute Ischemic Stroke. 2009. doi:10.1161/strokeaha.108.525626
46. Parsons et al. Combined (1)H MR spectroscopy and diffusion-weighted MRI improves the prediction of stroke outcome. *Neurology.* 2000 Aug 22;55(4):498-505.
47. Dogariu et al. Correlation between DWI-ASPECTS Score, Ischemic Stroke Volume on DWI, Clinical Severity and Short-Term Prognosis: A Single-Center Study. *Brain Sci.* 2024, 14, 577

LAMPIRAN

Lampiran 1. Hasil output SPSS

JenisKelamin

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Laki-Laki	15	65.2	65.2	65.2
	Perempuan	8	34.8	34.8	100.0
	Total	23	100.0	100.0	

Umur

N	Valid	23
	Missing	0
Mean		54.6522
Median		56.0000
Minimum		26.00
Maximum		73.00

Statistics

volume infark

N	Valid	23
	Missing	0
Mean		13.1796
Median		2.7000
Std. Deviation		28.64918
Range		134.69
Minimum		.31
Maximum		135.00

Statistics

Laktat

N	Valid	23
	Missing	0
Mean	185737.7391	
Median	173200.0000	
Std. Deviation	111797.17091	
Range	359536.00	
Minimum	48816.00	
Maximum	408352.00	

mRS

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	2.00	6	26.1	26.1	26.1
	3.00	4	17.4	17.4	43.5
	4.00	13	56.5	56.5	100.0
	Total	23	100.0	100.0	

Tests of Normality

	Kolmogorov-Smirnov^a			Shapiro-Wilk		
	Statistic	df	Sig.	Statistic	df	Sig.
volume infark	.327	23	.000	.476	23	.000
Laktat	.129	23	.200*	.916	23	.056

*. This is a lower bound of the true significance.

a. Lilliefors Significance Correction

Descriptives

	mRS		Statistic	Std. Error
volume infark	2.00	Mean	1.1600	.34503
		Median	1.0400	
		Std. Deviation	.84515	
		Minimum	.31	
		Maximum	2.29	
	3.00	Mean	3.3725	1.45435
		Median	3.0500	
		Std. Deviation	2.90869	
		Minimum	.43	
		Maximum	6.96	
	4.00	Mean	21.7446	10.07119
		Median	7.3000	
		Std. Deviation	36.31218	
		Minimum	.78	
		Maximum	135.00	
Laktat	2.00	Mean	101602.6667	25200.39734
		Median	69984.0000	
		Std. Deviation	61728.11481	
		Minimum	48816.00	
		Maximum	186944.00	
	3.00	Mean	156344.0000	73761.50092
		Median	91248.0000	
		Std. Deviation	147523.00185	
		Minimum	66272.00	
		Maximum	376608.00	

4.00	Mean	233613.5385	27139.59947
	Median	221248.0000	
	Std. Deviation	97853.21750	
	Minimum	107008.00	
	Maximum	408352.00	

Correlations

		Laktat	mRS
Spearman's rho	Laktat	Correlation Coefficient	1.000
		Sig. (2-tailed)	.
		N	23
	mRS	Correlation Coefficient	.602**
		Sig. (2-tailed)	.002
		N	23

** . Correlation is significant at the 0.01 level (2-tailed).

Correlations

		volume infark	mRS
Spearman's rho	volume infark	Correlation Coefficient	1.000
		Sig. (2-tailed)	.
		N	23
	mRS	Correlation Coefficient	.604**
		Sig. (2-tailed)	.002
		N	23

** . Correlation is significant at the 0.01 level (2-tailed).

Correlations

			Laktat	volume infark
Spearman's rho	Laktat	Correlation Coefficient	1.000	.755**
		Sig. (2-tailed)	.	.000
		N	23	23
	volume infark	Correlation Coefficient	.755**	1.000
		Sig. (2-tailed)	.000	.
		N	23	23

** . Correlation is significant at the 0.01 level (2-tailed).

Group Statistics

	dikotomi_mRS	N	Mean	Std. Deviation	Std. Error Mean
Laktat	1.00	6	101602.6667	61728.11481	25200.39734
	2.00	17	215432.4706	111370.7462	27011.37354

Independent Samples Test

		Levene's Test for Equality of Variances					t-test for Equality of Means		95% Confidence Interval of the Difference	
		F	Sig.	t	df	Sig. (2-tailed)	Mean Difference	Std. Error Difference	Lower	Upper
Laktat	Equal variances assumed	2.722	.114	-2.355	21	.028	-113829.804	48327.09552	-214331.501	-13328.10700
	Equal variances not assumed			-3.081	16.346	.007	-113829.804	36941.49871	-192007.727	-35651.88118

Area Under the Curve

Test Result Variable(s): Laktat

Area	Std. Error ^a	Asymptotic Sig. ^b	Asymptotic 95% Confidence Interval	
			Lower Bound	Upper Bound
.833	.101	.017	.635	1.000

a. Under the nonparametric assumption

b. Null hypothesis: true area = 0.5

Coordinates of the Curve

Test Result Variable(s): Laktat

Positive if Greater Than or Equal To ^a	Sensitivity	1 - Specificity	Youden index
48815.0000	1.000	1.000	0
54424.0000	1.000	.833	0,167
62944.0000	1.000	.667	0,333
66064.0000	1.000	.500	0,5
70192.0000	.941	.500	0,441
77872.0000	.941	.333	0,608
91248.0000	.882	.333	0,549
103936.0000	.824	.333	0,491
110728.0000	.765	.333	0,432
125704.0000	.706	.333	0,373
148272.0000	.647	.333	0,314
166392.0000	.588	.333	0,255
173528.0000	.529	.333	0,196
180400.0000	.529	.167	0,362
199200.0000	.529	.000	0,529
216352.0000	.471	.000	0,471
236200.0000	.412	.000	0,412
253944.0000	.353	.000	0,353
277824.0000	.294	.000	0,294
303600.0000	.235	.000	0,235
342448.0000	.176	.000	0,176
383120.0000	.118	.000	0,118
398992.0000	.059	.000	0,059
408353.0000	.000	.000	0

Lampiran 2. Rekomendasi Persetujuan Etik



KEMENTERIAN PENDIDIKAN, KEBUDAYAAN, RISET DAN TEKNOLOGI
 UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN
 KOMITE ETIK PENELITIAN UNIVERSITAS HASANUDDIN
 RSPTN UNIVERSITAS HASANUDDIN
 RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR
 Sekretariat : Lantai 2 Gedung Laboratorium Terpadu
 JL.PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.
 Contact Person: dr. Agusallim Bukhari.,MMed,PhD, SpGK TELP. 081241850858, 0411 5780103, Fax : 0411-581431



REKOMENDASI PERSETUJUAN ETIK

Nomor : 803/UN4.6.4.5.31/ PP36/ 2024

Tanggal: 30 September 2024

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH24090702	No Sponsor	
Peneliti Utama	dr. Rowin	Sponsor	
Judul Peneliti	KORELASI NILAI LAKTAT SPECTROSCOPY DAN VOLUME INFARK DWI MENGGUNAKAN MRI 3T PADA PASIEN STROKE ISKEMIK AKUT TERHADAP LUARAN KLINIS MENGGUNAKAN MODIFIED RANKIN SCALE		
No Versi Protokol	1	Tanggal Versi	17 September 2024
No Versi PSP		Tanggal Versi	
Tempat Penelitian	RSUP Dr.Wahidin Sudirohusodo Makassar		
Jenis Review	<input type="checkbox"/> Exempted <input checked="" type="checkbox"/> Expedited <input type="checkbox"/> Fullboard Tanggal	Masa Berlaku 30 September 2024 sampai 30 September 2025	Frekuensi review lanjutan
Ketua KEP Universitas Hasanuddin	Prof. dr. Muh Nasrum Massi,PhD,SpMK, Subsp. Bakt(K)	Tanda tangan 	
Sekretaris KEP Universitas Hasanuddin	dr. Firdaus Hamid, PhD, SpMK(K)	Tanda tangan 	

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Laporan SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari protokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan

Lampiran 3.

Curriculum Vitae

Data Umum

Nama : dr. Rowin
Tempat/ Tanggal Lahir : Pekanbaru, 25 Agustus 1993
Alamat : Jl. Kw. Pergudangan dan industri Parangloe,
Perumahan Akasia Blok A3 no 37, Tamalanrea,
Makassar
Jenis kelamin : Laki-laki
Telepon : +6282173973210
Agama : Islam
Status : Menikah
Pekerjaan : Dokter

Pendidikan:

2011-2015: **SARJANA KEDOKTERAN** – Universitas YARSI, Jakarta – indonesia.

2015-2017: **PENDIDIKAN PROFESI DOKTER** – Universitas Yarsi, Jakarta – Indonesia.

2017-2018: **INTERNSHIP**: RSUD Pademangan, Jakarta – Indonesia.

2018: **ACLS Training** – PERKI – Indonesia.

2021-Sekarang : **PENDIDIKAN DOKTER SPESIALIS** – Universitas Hasanuddin, Makassar – Indonesia.

Pengalaman Kerja:

2018-2019: Dokter umum, Eka Hospital, Pekanbaru, Indonesia.

Karya Ilmiah/Resource Papers:

KORELASI NILAI LAKTAT *SPECTROSCOPY* DAN VOLUME INFARK DWI MENGGUNAKAN MRI 3T PADA PASIEN STROKE ISKEMIK AKUT TERHADAP LUARAN KLINIS MENGGUNAKAN *MODIFIED RANKIN SCALE*

Symposium / Acara Ilmiah:

1. Symposium dan Workshop 11th Annual Scientific Meeting Indonesian Society Of Thoracic Radiology, PIT Radiologi Toraks 2023, Jakarta.
2. Symposium Radiology : A New Hope, 17th Annual Scientific Meetings Indonesian Society Clinical Of Radiology, PIT PDSRKI 2024, Jakarta.